Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib…
<!-- Name:DistributionId Value:8809812 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
wet amd
Clinical trials results demonstrate value of home OCT at international meetings
<!-- Name:DistributionId Value:8753696 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->…
Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the…
<!-- Name:DistributionId Value:8741270 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4533 -->…
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with…
<!-- Name:DistributionId Value:8741606 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular…
Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight
New York, USA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight DelveInsight’s Wet AMD pipeline analysis depicts a robust space with 70+ active players working to…
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib…
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the…
Graybug to Present at the 2022 OIS Retina Innovation Summit
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform…
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the…
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa…
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b…
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for patients participating in Extension StudyGB-102 1mg…